These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1727128)

  • 1. Selection of reagents for human radioimmunotherapy.
    Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
    Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
    Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
    J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
    Vriesendorp HM; Morton JD; Quadri SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
    Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
    J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy.
    Vriesendorp HM; Quadri SM; Jaeckle KA; Freedman RS; Cromeens DM
    Radiother Oncol; 1996 Nov; 41(2):151-61. PubMed ID: 9004359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
    Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
    Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic side effects of radiolabeled immunoglobulin therapy.
    Vriesendorp HM; Quadri SM; Andersson BS; Dicke KA
    Exp Hematol; 1996 Aug; 24(10):1183-90. PubMed ID: 8765492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
    Vriesendorp HM; Quadri SM
    Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
    Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
    J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
    Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
    Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.
    Vriesendorp HM; Quadri SM; Wyllie CT; Lai J; Borchardt PE; Harris L; Wucher R; Askew E; Schweichler L
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3324s-3329s. PubMed ID: 10541381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
    Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
    Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.